ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: DETAILED SAFETY ANALYSIS FROM THE RANDOMIZED PHASE 3 HERO STUDY

被引：0
|
作者：
Mehlhaff, Bryan
Shore, Neal D.
George, Daniel J.
Cookson, Michael S.
Saltzstein, Daniel R.
Tutrone, Ronald
Bailen, James L.
Brown, Bruce
Langenberg, Andria G. M.
Fallick, Mark
Lu, Sophia
Hanson, Sarah
Tombal, Bertrand
Saad, Fred
机构：
来源：
JOURNAL OF UROLOGY | 2022年 / 207卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP27-16
引用
收藏
页码：E456 / E456
页数：1
相关论文
共 50 条
  • [1] ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: POOLED SAFETY ANALYSES FROM RANDOMIZED CONTROLLED STUDIES
    Bailen, James L.
    Saad, Fred
    George, Daniel J.
    Mehlhaff, Bryan
    Cookson, Michael S.
    Saltzstein, Daniel R.
    Tutrone, Ronald
    Brown, Bruce
    Langenberg, Andria G. M.
    Lu, Sophia
    Lee, Jina
    Hanson, Sarah
    Tombal, Bertrand
    Shore, Neal D.
    JOURNAL OF UROLOGY, 2022, 207 (05): : E630 - E630
  • [2] Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
    Shore, Neal D.
    Saad, Fred
    Cookson, Michael S.
    George, Daniel J.
    Saltzstein, Daniel R.
    Tutrone, Ronald
    Akaza, Hideyuki
    Bossi, Alberto
    van Veenhuyzen, David F.
    Selby, Bryan
    Fan, Xiaolin
    Kang, Vicky
    Walling, Jackie
    Tombal, Bertrand
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23): : 2187 - 2196
  • [3] Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer
    Chow, Alexander K.
    Vourganti, Srinivas
    Konety, Badrinath R.
    EUROPEAN UROLOGY, 2021, 80 (03) : 386 - 386
  • [4] Re: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
    不详
    JOURNAL OF UROLOGY, 2021, 205 (01): : 303 - 304
  • [5] Relugolix - The novel oral androgen deprivation therapy for prostate cancer
    Jena, Rahul
    INDIAN JOURNAL OF UROLOGY, 2020, 36 (04) : 327 - 328
  • [6] Efficacy and safety of relugolix in black men with advanced prostate cancer: A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide.
    George, Daniel J.
    Saad, Fred
    Pieczonka, Christopher Michael
    Cookson, Michael
    Saltzstein, Daniel
    Tutrone, Ronald F.
    Brown, Bruce
    Lu, Sophia
    Fallick, Mark
    Hanson, Sarah
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [7] Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
    Saad, Fred
    Shore, Neal D.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [8] Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer
    Adekunle, Olajide A.
    Seoane-Vazquez, Enrique
    Brown, Lawrence M.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2023, 63 (03) : 817 - 824.e3
  • [9] Impact of age on efficacy and safety of relugolix: A subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer.
    Cookson, Michael
    Shore, Neal D.
    George, Daniel J.
    Akaza, Hideyuki
    Saltzstein, Daniel
    Tutrone, Ronald F.
    Bossi, Alberto
    Brown, Bruce
    Selby, Bryan
    Lu, Sophia
    Walling, Jacqueline M.
    Tombal, Bertrand F.
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Efficacy and safety of relugolix in Asian men with advanced prostate cancer (APC): A subgroup analysis from the randomized, phase III HERO study versus leuprolide
    Ye, D.
    Choi, Y. D.
    Brown, B.
    Lu, S.
    Xu, Q. Q.
    Uemura, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1497 - S1497
12345